MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
"Triple Helix" Innovation Model
4. Triple Helix _ Capture Strategies
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: Ireland
AbbVie Inc. (NYSE:ABBV)
Finance & Acquisition: AbbVie
ImmunoGen Inc. (NASDAQ: IMGN)
Organization & Developments: Immunogen
Parents
ImmunoGen Inc. (NASDAQ: IMGN)
Children
2011: Genentech uses ImmunoGen’s technology to help amp up the antibody trastuzumab (Herceptin) into a more potent breast cancer drug called T-DM1, which has shown significant promise in clinical trials (2011)
2017: ImmunoGen inks ADC development deal with Jazz Pharma valued at least $175M; shares ahead 11% premarket - ImmunoGen, Inc. (NASDAQ:IMGN)
2019: ImmunoGen: A Long-Term Investment Based On Its ADC Technology_seekingalpha.com
2019: ImmunoGen: Bold Move To Position A Comeback_seekingalpha.com
2019: ImmunoGen: Profiting And Turning Around_seekingalpha.com
2019: ImmunoGen: The Comeback Kid_seekingalpha.com
2019: Rebound In Focus: ImmunoGen_seekingalpha.com
2019: Turned back at the FDA, ImmunoGen is axing 220 staffers, selling programs and hunkering down for a new PhIII gamble – Endpoints News
2020: ImmunoGen: Update On A Turnaround Story
2021: ImmunoGen: Important Catalysts Ahead
2021: ImmunoGen: Major Catalysts This Year
2021: ImmunoGen: Turning Around Amid A Bearish Environment
2022: ImmunoGen Before The PDUFA_ seekingalpha.com
2022: ImmunoGen Needs To Make The Most Of Its First-Mover Opportunity_ seekingalpha.com
2022: ImmunoGen: Elucidating Ramifications Of The Elahere Approval_ seekingalpha.com
2023: ImmunoGen: Elahere Data Mid-2024 To Expand Targeted Population_ seekingalpha.com
2023: ImmunoGen: Making A Successful Comeback_ seekingalpha.com
2023: ImmunoGen: Shares Take Flight On Ovarian Cancer Survival Data - What Happens Next?_ seekingalpha.com
2023: ImmunoGen's Elahere Breakthrough Offers Hope For Patients And Investors Alike_ seekingalpha.com
2023: ImmunoGen’s ovarian cancer treatment helps patients live longer than chemo in confirmatory trial
Targeted Antibody Payload (TAP) technology
Waltham, Massachusetts
Jumps
*Key People: Immunogen
Finance & Acquisitions: Immunogen